Skip to content
Business Times – Lifestyle
Author:
BioNTech SE
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
October 25, 2026
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
October 22, 2026
BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026
October 20, 2026
BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
October 19, 2026
BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
October 13, 2026
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
September 14, 2026
BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
August 4, 2026
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
August 3, 2026
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
July 29, 2026
BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
July 21, 2026
1
2
Next Page
→